PDCD1 and neoplasm: Identification of these immunosuppressive pathways led to the development of monoclonal antibody (mAb)-based cancer therapies that inhibit PD-1/PD-L1 or CTLA-4/B7 pathways, thereby reinvigorating the host anti-tumor immune response [2,13,14,15,16,17].